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Electroporation for the Delivery of DNA-based
Vaccines and Immunotherapeutics: Current
Clinical Developments
Angela M Bodles-Brakhop1, Richard Heller2 and Ruxandra Draghia-Akli1
1
Research, VGX Pharmaceuticals, Inc., The Woodlands, Texas, USA; 2Frank Reidy Research Center for Bioelectrics, Old Dominion University,
Norfolk, Virginia, USA

Electroporation (EP) has been used in basic research for the past 25 years to aid in the transfer of DNA into
cells in vitro. EP in vivo enhances transfer of DNA vaccines and therapeutic plasmids to the skin, muscle,
tumors, and other tissues resulting in high levels of expression, often with serological and clinical benefits.
The recent interest in nonviral gene transfer as treatment options for a vast array of conditions has resulted in
the refinement and optimization of EP technology. Current research has revealed that EP can be successfully
used in many species, including humans. Clinical trials are currently under way. Herein, the transition of EP
from basic science to clinical trials will be discussed.
Received 6 November 2008; accepted 27 December 2008; published online 17 February 2009. doi:10.1038/mt.2009.5

Introduction
According to the Journal of Gene Medicine there are 246 clinical trials worldwide investigating naked plasmid DNA (www.
wiley.co.uk/genmed/clinical), representing almost 20% of all
vectors used in clinical trials and coming in third place behind
adenovirus (24.8%) and retrovirus (22.3%) vectors. The development of novel nonviral vaccines and therapeutics for the
prevention or treatment of disease has warranted the development of a delivery system that enables satisfactory expression
of the desired molecule. Viral transfection systems have classically resulted in high expression levels of transgene products;
however, this approach has immunological drawbacks1 and
has led to nonviral vectors increasingly becoming the vehicle
of choice. To boost efficacy of nonviral gene therapies several
delivery methods have been under investigation such as lipidmediated entry into cells,2 jet injection, gene gun delivery,3 and
sonoporation.4 In this review we will focus on electroporation
(EP) whereby cellular membranes are transiently destabilized
by localized and controlled electric fields, facilitating the entry
of foreign molecules into cells and tissues.5 Although the exact
mechanism of cellular macromolecule entry is still under discussion, entry of small molecules such as anticancer drugs
seems to occur by simple diffusion after the pulse, and larger
molecules such as plasmid DNA are thought to enter through
a multistep mechanism involving the interaction of the DNA
molecule with the destabilized membrane during the pulse and
then its passage across the membrane.6
The technique of EP has been used for over 25 years as a
means of introducing macromolecules, including DNA, into
cells in vitro,7 and is now widely used for transfection of plasmids into different tissues in vivo.8 More recently, EP has been

used for the application of DNA vaccines and gene therapies.
However, the transition of EP to the clinical setting has been
slow to progress. Initially, the administration of bleomycin, an
anticancer agent that induces DNA strand breaks, in combination with EP was the subject of numerous preclinical studies
(reviewed in ref. 9) and tested in several humans with the first
clinical trials started >15 years ago.10,11 Of note, pivotal studies performed around the same time demonstrated for the first
time effective macromolecule in vivo EP in tumors,12 liver,13,14
and skeletal muscle.15
Although other physical delivery methods, such as ultrasound, have been used recently in small animal settings,16
successful small and large animal including nonhuman primate
studies and human clinical trials using EP have demonstrated
the effectiveness of this technique with plasmids. Overall, the
technique of EP has been shown to be a versatile approach, as
delivery has been accomplished across several species, different
types of cells and tissues, EP conditions, macromolecule types,
and most importantly, a large spectrum of applications. Several
clinical trials are now investigating EP as a medical technology
in humans, as shown in Figure 1.
Various well-designed preclinical studies have been stepping
stones in the progression to clinics (reviewed in refs 17–20).
While diverse in scope and approaches, the ability to provide
sound evidence and preliminary findings in laboratory or
companion animals have proven crucial for the design of successful clinical trials. Furthermore, the development of naked
DNA and EP technology in animals not only provides the
basis for human studies but also lays the foundation for veterinary medical advances and bridges the gap between the two
disciplines.21–25 The preclinical studies that have led to the
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Figure 1 Clinical trials using electroporation. (a) Seven gene therapy
trials are listed on regulatory Web sites and investigate the benefits of
EP; out of these, two are examining the tolerability of the technology.
Five trials are investigating the combination of EP with nongene therapy
approaches (anticancer drugs) for the treatment of cancer. One completed nongene therapy study by Merck tested the tolerability of EP
in healthy adults. The number of trials is presented as a percentage.
(b) Conditions addressed by EP clinical trials. Four trials examining the
potential of EP in the treatment of melanoma. For all other conditions
there is presently just one trial. Five of the trials (one head and neck
cancer, one melanoma, one pancreatic cancer, one breast cancer, and one
cutaneous/subcutaneous cancer) involve non-gene therapy approaches.
The number of trials is presented as a percentage.

clinical trials for various conditions shown in Table 1 will be
discussed.

Melanoma
Cytokines
The use of recombinant cytokines has provided a glimmer of
hope in the fight against cancer; however, the frequent systemic
administration of high doses often leads to dose-limiting side
effects and toxicity.26 Therefore, new treatment strategies are in
high demand. Interleukin (IL)-2 and IL-12 have shown promising
antitumor effects in numerous preclinical studies by improving
immune responses although the exact mechanism has yet to be
elucidated.27–29
Previous studies have examined the treatment of mice bearing
murine ovarian teratocarcinoma with IL plasmid DNA complexed with a cationic lipid.30 The administration of IL-2 pDNA
increased the local concentration of the expressed cytokine and
extended the length of expression from 24 hours for the recombinant form to up to 10 days for the plasmid DNA. Furthermore,
the results showed that there was a significant antitumor effect as
well as a significant increase in survival. Combining the delivery
of bleomycin with IL-2 plasmid using EP resulted in long-term
disease free survival in a mouse melanoma model.31
586

Nonclinical investigational new drug (IND) applicatione nabling studies in mice evaluated the effect of intratumoral
murine IL-2 pDNA on local expression and systemic distribution
of IL-2 transgene, as well as the inhibition of established tumor
growth.32 Results showed that EP-assisted delivery produced the
highest levels of IL-2 in the tumor (3–7 times higher than without
EP). Local sustained levels of IL-2 within the tumor and relatively
low, short-lived serum levels were detected. Tumor regression was
noted with IL-2 plus EP compared to IL-2 alone. Further studies
testing the safety of repeated s.c. administrations of VCL-IM01
[human IL-2 pDNA (VCL-1102) in PBS] with EP were carried
out in rats. There were no mortalities, no evidence of drug-related
toxicity, no erythema associated with injection or EP, and overall
treatment was well tolerated. These preclinical findings, in combination with previously published safety study results for VCL-1102
pDNA,33 led to the ongoing clinical testing of VCL-IM01 with EP
in a phase I clinical trial (ClinicalTrials.gov ID NCT00223899).
Thirty patients with metastatic melanoma are scheduled to receive
VCL-IM01 at various dose concentrations intratumorally followed
by EP using the Medpulser EPT System. The primary endpoint of
the study is safety, with secondary outcomes including response
rate, assessment of injected tumors for induration, inflammation,
and erythema, and serum levels of IL-2. Tumor burden, response
rate, and disease progression will also be assessed.
The success of the administration of plasmid IL-2 led to studies examining the potential of IL-12 in combination with EP in
murine melanoma tumor models. A local antitumor effect with
reduced systemic cytokine levels was observed.34 The combination of EP with either murine IL-2 or IL-12 plasmids resulted in a
significant growth delay of ~5–15 days compared to control plasmid plus EP and the respective naked cytokine plasmids without
EP.34 Further studies demonstrated that intratumoral injection of
plasmid IL-12 with EP of mice with B16.F10 melanoma tumors
resulted in 80% being tumor free for >100 days and resistant to
challenge with B16 cells.35,36 To facilitate the translation of this
approach to the clinic, toxicity was evaluated in the B16.F10
melanoma model. Expression levels of IL-12 were significantly
increased when delivered with EP in addition to complete regression of tumors, when plasmid IL-12 was delivered with EP, the
findings showed minimal to no toxicity.37
The phase I trial of intratumoral pIL-12 EP in patients with
Stage IIIB/c or IV malignant melanoma (n = 24) (ClinicalTrials.
gov ID NCT00323206) was designed to determine safety and tolerability, the correct dose of this type of treatment, and also its
effectiveness in treating melanoma. EP was performed using the
Medpulser EPT System. Primary outcome measures included
toxicity profile, maximum-tolerated dose, recommended dose for
a phase II study, local and systemic response, and local and systemic expression of IL-12 and IFN-γ. An increase in IL-12 and
IFN-γ was observed locally within treated tumors but no increase
in serum levels was seen. Biopsies of treated lesions revealed
marked necrosis and lymphocytic infiltration. In addition, 8 of
the 24 patients were observed to have stable disease and two of
them had a complete response of all lesions, treated and untreated.
This first human trial investigated IL-12 gene transfer utilizing
in vivo DNA EP in metastatic melanoma and showed that it is
safe, effective, reproducible, and titratable.38
www.moleculartherapy.org vol. 17 no. 4 apr. 2009
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Table 1 Clinical trial cases involving gene therapy and electroporation
NCT or GT ID

Phase Status

Sponsor

Condition

Intervention

Primary objective

Metastatic
Melanoma

Intratumoral VCL-IM01
(encoding IL-2) with Inovio
MedPulser device

Safety and efficacy,
dose escalation

NCT00223899

I

Active, not recruiting Vical

NCT00323206

I

Recruiting

H. Lee Moffitt Cancer Center Malignant
and Research Institute;
Melanoma
National Gene Vector
Laboratory

Intratumoral IL-12 pDNA with
Inovio MedPulser device

Toxicity and efficacy,
recommended dose
for phase II study,
local, and systemic
response

NCT00471133

I

Recruiting

Ichor Medical Systems
Incorporated; Memorial
Sloan-Kettering Cancer
Center

Melanoma (Skin);
Intraocular
Melanoma

Biological: Xenogeneic
Tyrosinase DNA Vaccine;
Device: TriGrid IM
electroporation delivery system

Safety and
immunogenicity

NCT00545987

I

Active, not recruiting Rockefeller University;
Aaron Diamond AIDS
Research Center; Bill and
Melinda Gates Foundation;
Ichor Medical Systems
Incorporated; International
AIDS Vaccine Initiative

HIV Infections

ADVAX DNA-based HIV
vaccine TriGrid EP delivery
system

Safety and
immunogenicity

NCT00685412

I

Recruiting

VGX Pharmaceuticals Inc.

Papillomavirus
Infections

Biological: VGX-3100 via EP
Safety and tolerability
using the CELLECTRA constant of escalating doses
current device

NCT00721461

I

Completed

Merck; University of
Healthy
California, San Diego; Inovio
Biomedical Corporation

IM injection of phosphatebuffered saline solution Inovio
MedPulser device

NCT00563173

I/II

Recruiting

Tripep AB; Inovio
Biomedical Corporation

Chronic
Hepatitis C Virus
Infection

IM administered
Safety, tolerability,
CHRONVAC-C in combination and efficacy
with Inovio MedPulser device

UK-112

I/II

Ongoing

Cancer Research UK
Oncology Unit,
Southampton, UK

Prostate cancer

Prostate-specific membrane
—
antigen (PSMA)/pdom fusion
gene, IM injection with or
without Inovio MedPulser device

Tolerability of the
MedPulser DNA
delivery system

Abbreviations: EP, electroporation; IM, intramuscular.
Note: NCT ID Web site www.ClinicalTrials.gov (Clinical Trials.gov); GT ID Web site http://www.wiley.com/legacy/wileychi/genmed/clinical/ (gene therapy clinical
trials worldwide).

The preclinical findings indicate that the application of cytokines alone can improve efficacy but the addition of EP can further enhance their therapeutic potential. The clinical trials will
hopefully demonstrate that the combination of EP with cytokineexpressing plasmids will be effective in treating humans with
melanoma.

Xenogeneic tyrosinase DNA vaccine
The tyrosinase family proteins are well-characterized differentiation antigens recognized by antibodies and T cells of patients with
melanoma. Preclinical mouse studies revealed that xenogeneic
DNA vaccination with genes encoding tyrosinase family members
can induce antibody and cytotoxic T cell responses resulting in
tumor rejection.39,40 The addition of EP for administration of
plasmid encoding, a novel construct of autologous, melanocyte
antigen tyrosinase–related protein-2, resulted in very high numbers of CD8+ T cells and significant delay in tumor growth after
challenge in mice.41 These results led to the examination of the
long-term survival of dogs with advanced spontaneous malignant
melanoma after DNA vaccination with xenogeneic human tyrosinase in a single-arm phase I trial.42,43 Nine dogs were injected
Molecular Therapy vol. 17 no. 4 apr. 2009

with human tyrosinase plasmid DNA intramuscularly (IM) via a
different methodology, using Biojector2000, a needle-free delivery
device. The trial demonstrated that the vaccination was safe and
efficacious. The median survival time for all vaccinated dogs was
just over 1 year compared to dogs treated using historical controls
with conventional therapies that survived 1–5 months. Antibody
responses were documented in a follow-up publication, with three
out of the nine dogs showing a response.44
Based on these encouraging results, a phase I trial of mouse
and human TYR DNA vaccines in 18 stage-III/IV melanoma
patients was conducted to assess safety and immunogenicity
using the Biojector2000.45 This needle-free injection system was
well tolerated and T cell responses were detected in seven patients.
Median survival time had not been determined after >42 months
follow-up, at the time of study publication. The results of this
study and the advent of efficacious EP devices have led to the
larger evaluation of various DNA delivery methods including a
phase I clinical trial investigating the safety and immunogenicity
of xenogeneic tyrosinase DNA vaccine, administered IM with EP
to patients with stage IIB, IIC, III, or IV melanoma (ClinicalTrials.
gov ID NCT00471133). Primary outcome measures include
587
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evaluation of the safety and feasibility of EP-mediated IM delivery
and assessment of the magnitude and frequency of tyrosinase-specific immunologic responses in the immunized patients. Patients
with measurable tumors will be assessed for evidence of antitumor responses following immunization. The ability of xenogeneic
tyrosinase DNA vaccine in combination with EP will hopefully
lead to even greater increases in immune responses, antitumor
effects, and increased longevity compared to the vaccine alone.

Hiv Infections
Since the identification of the causative agent of acquired immunodeficiency syndrome (AIDS) in the early 1980s progress toward
an effective vaccine has been hindered by the pathogenesis of the
virus itself. Although current treatment with antiretroviral drugs
can turn this fatal disease into a manageable chronic condition,
the need for a novel therapeutic strategy is without question to
control the AIDS pandemic.
Attempts at developing an effective AIDS vaccine led to
the recent STEP AIDS vaccine study by Merck. The STEP HIV
vaccine trial used a modified recombinant adenovirus serotype
5 (rAd5) as a vaccine vector along with three synthetically produced HIV genes (gag, pol, and nef).46 The phase I and phase II
human clinical trials were suspended based on an interim data
review that concluded that the vaccine could not be shown to prevent HIV infection or reduce the amount of virus in those who
became infected (ClinicalTrials.gov Identifier: NCT00486408 and
NCT00413725). Further analysis of the study suggested that those
participants who received the vaccine were more susceptible to
HIV infection, especially those who had higher levels of preexisting immunity (antibodies) to Ad5 due to prior natural exposure
to that particular type of cold virus. (http://www3.niaid.nih.gov/
news/QA/step_qa.htm). Nevertheless, the lessons learned from
these trials are invaluable, and establish the basis for the next
generation of vaccines.
One method to overcome the issue of preexisting immunity, which was problematic in the STEP trial, is the use of DNA
vaccines in place of their viral counterparts. Numerous studies and
clinical trials are examining the potential of DNA vaccines as HIV
therapeutics. In a phase I trial, the safety and immunogenicity of
a multigene, polyvalent HIV-1 DNA plasmid prime/Env protein–
boost vaccine formulation was evaluated in healthy volunteers
(ClinicalTrials.gov Identifier: NCT00061243) demonstrating
T cell responses as well as high-titer serum antibody responses.47
The combination of a DNA vaccine with cytokines indicated
that memory-immune responses in SIV-infected macaques were
enhanced.48
Further studies have demonstrated that the route and dose of
DNA vaccine is critical for optimal immune responses.49 Results
of a phase I trial demonstrated that vaccination with a DNA prime
formulation followed by a protein boost for seronegative adults
induced HIV-1-specific T cells and anti-Env antibodies capable
of neutralizing cross-clade viral isolates. Additional studies examined vaccination with a low dose of DNA administered intradermic (ID) compared with low or high dose of DNA administered
IM. Each group subsequently received one or two doses of the
gp120 protein–boost vaccine IM. The high dose, administered
IM, resulted in a greater response than ID after DNA vaccination.
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However, after the second protein boost, the magnitude of T cell
responses in the ID group was indistinguishable from those in
the other two groups. The need for a prime/boost strategy in this
case was important for a quality immune response. In another
phase I trial, patients who received four IM immunizations with
a DNA vaccine did not differ statistically in rate of response from
placebo controls.50 It would seem, therefore, that the route of
administration and the dose are both extremely important for
success. Nevertheless, other studies have shown that the efficacy
of the prime/boost vaccination regime by needle injection can be
improved and simplified by the use of EP.
Several studies have examined the potential of EP in the
administration of a HIV vaccine. In mice, in vivo EP amplified
cellular and humoral immune responses to a HIV type 1 Env DNA
vaccine, enabled a tenfold reduction in vaccine dose, and resulted
in an increased recruitment of inflammatory cells.51 Nonhuman
primate studies examined four different administration strategies, namely, DNA by IM injection, DNA with plasmid-encoded
IL-12 by IM injection, DNA by IM injection with in vivo EP, and
DNA with IL-12 by IM EP.52 Each group was immunized three
times with optimized HIV gag and env constructs. The combined approach of cytokine adjuvant and EP resulted in dramatically higher cellular as well as humoral responses and a tenfold
increase in antigen-specific IFN-γ(+) cells compared to IM DNA
immunization. Further studies supporting these findings demonstrated that an optimized HIV gag expression plasmid administered by EP resulted in an expansion of antigen-specific CD4+
and CD8+ T cells of both central and effector memory phenotype
in SIV-infected animals.53 These studies all utilized the IM route
of administration, but ID EP administration of an HIV DNA
vaccine in nonhuman primates has also been shown to be effective at inducing high-humoral and cellular-immune responses
compared to ID injection alone.54 Other studies show that EP of
low-dose HIV env elicited Th1 cytokines and antienvelope antibodies. The subsequent boosting of DNA-primed animals with
gp120 proteins administered with either QS-21, or the orally
administered immunomodulator, Talabostat, has been shown to
augment cellular immune responses.55–57
The safety and immunogenicity of a plasmid HIV vaccine,
ADVAX env/gag + ADVAX pol/nef-tat (ADVAX), is being
examined in an ongoing phase I trial in HIV uninfected
adults (ClinicalTrials.gov Identifier: NCT00249106) and in
combination with EP as a potential protective vaccine against HIV
(ClinicalTrials.gov Identifier: NCT00545987). The dual-promoter
multigenic DNA vaccine capable of high-level expression of two
independent transgenes was designed and constructed.58 HIV-1
gag, pol, env, nef, and tat from a primary subtype C/B´ CCR5tropic HIV-1 were codon optimized and then modified to remove
known functional activity, and assembled using an overlapping
polymerase chain reaction into two plasmids, namely, ADVAX-I
(containing env and gag) and ADVAX-II (containing pol and
nef-tat). In this randomized, placebo-controlled, dose-escalating,
double-blinded phase I study local and systemic reactogenicity
signs and symptoms as well as adverse effects were investigated
after the administration of one to three doses of ADVAX. This
has led to the current study that is recruiting participants to test
the safety and immunogenicity of an IM injection of two doses
www.moleculartherapy.org vol. 17 no. 4 apr. 2009
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of ADVAX using the EP TriGrid Delivery System (Ichor Medical
Systems, ClinicalTrials.gov Identifier: NCT00545987). Of note,
this trial is investigating the prophylactic potential of a DNA
vaccine administered by EP and is part of a broader research effort
to determine whether changes in the way vaccines are administered can make them more effective.

Human Papillomavirus Infections
Human papillomavirus (HPV) infection is the major cause of
cervical cancer. Although the recently FDA-approved HPV
vaccine Gardasil has been shown to prevent infection, it does not
provide treatment for individuals already infected. Therefore, the
development of a therapeutic HPV vaccine is of great importance.
The HPV genome encodes two HPV late genes, L1 and L2, which
form the viral capsid. Early viral proteins support viral genome
replication, two of which (E6 and E7) are important for HPVassociated malignant transformation. Prophylactic vaccines target
the HPV capsid protein L1, thereby preventing infection, whereas
therapeutic HPV vaccines target the E6 and E7 proteins.59
Studies have demonstrated that DNA vaccines can induce
CTL responses and antitumor activity. Administration of a codonoptimized HPV-16 E6 DNA vaccine (pNGVL4a-E6/opt) resulted
in significantly enhanced E6-specific CD8+ T cell immune
responses in mice. Protective and therapeutic antitumor effects
were also noted against challenge.60 Other groups report that a
DNA vaccine–encoding calreticulin (CRT) linked to HPV-16 E7
generated potent E7-specific CD8+ T cell-immune responses and
antitumor effects against an E7-expressing tumor.61 Furthermore,
development of a similar DNA vaccine encoding CRT linked to
E6 (CRT/E6) generated significant T cell responses and could
protect mice from challenge.62
An earlier study utilized the technique of EP for the introduction of plasmids that express antisense RNA of the E6 and
E7 genes on the growth of HPV positive human cancer cell lines
resulting in slowed growth.63 Several other studies are examining the potential of EP for administration of dendritic cell–based
tumor vaccines.64,65
Strong cellular immune responses can be induced in both mice
and nonhuman primates following the administration with EP of
a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus
protein.66 These finding have lead to a phase I study using a DNA
vaccine, VGX-3100, which includes plasmids targeting E6 and E7
proteins of both HPV subtypes 16 and 18 that will be delivered
using the constant current CELLECTRA EP device following
IM injection (ClinicalTrials.gov identifier: NCT00685412). This
study will determine the dose, safety, and tolerability as well as
the humoral and cellular immune responses in adult female subjects’ postsurgical or ablative treatment of grade 2 or 3 cervical
intraepithelial neoplasia.

Hepatitis C
Hepatitis C is a blood-borne infectious disease that is caused by
hepatitis C virus (HCV) infecting hepatocytes with almost one
third of infected individuals progressing to liver disease. No
vaccine against hepatitis C is available and current treatment
strategies are insufficiently effective, poorly tolerated, and expensive. A DNA vaccine encoding cell-surface HCV-envelope 2 (E2)
Molecular Therapy vol. 17 no. 4 apr. 2009

glycoprotein was shown to stimulate strong immune responses in
mice and rhesus macaques. Immunization of chimpanzees did not
result in protection from challenge but prevented progression to a
chronic state.67 Therefore, the development of novel vaccines and
delivery methods will be important in treating this highly prevalent infection.
To this end, a synthetic nonstructural (NS) NS3/4A-based
DNA vaccine was generated in which the codon usage was optimized for human cells.68 In a study examining the in vivo EP of
the HCV NS3/4A DNA vaccine revealed increased and prolonged
expression of protein levels as well as an increased infiltration
of CD3+ T cells at the site of injection, likely contributing to an
observed enhancement of CD4+ T cells, CD8+ T cells, and IFN-γ
production. The increase in CD8+ T cells resulted in the elimination of HCV NS3/4A-expressing liver cells in transiently transgenic mice.69 In a separate study, a construct encoding a HCV
genotype 1a/1b consensus immunogen of proteins NS3/4A was
used to immunize mice followed by IM EP. Results show that
strong anti-NS3/4A T cell responses in mice as well as in rhesus
macaques were induced.70 In mice and nonhuman primates, EP of
a DNA vaccine encoding an optimized version of the NS region of
HCV (from NS3 to NS5B) induced strong and long-lasting CD4+
and CD8+ cellular immunity compared to naked DNA injection
alone.71 Furthermore, in the same study, vaccination with EP produced a higher CD4+ T cell response than an adenovirus 6-based
viral vector encoding the same antigen.
Currently, there is one clinical trial evaluating the administration of the DNA vaccine CHRONVAC-C by IM injection with EP
using the Inovio Elgen system. CHRONVAC is a therapeutic vaccine given to individuals already infected with HCV. Early results
indicate that the first two patients given the intermediate dose
of CHRONVAC-C with EP had reduced viral loads (by 87 and
98%) and that there may be a dose-dependent correlation between
T cell responses generated and reduction in hepatitis C viral
load. No severe adverse effects have been noted (http://tripep.se/
english/news/press_releases/?id=2008063020130). These findings
are extremely promising for the continued development of DNA
vaccines and the use of EP for treatment of hepatitis C.

Prostate Cancer
Prostate cancer is one of the most common types of cancer in
men. Treatment options for prostate cancer are primarily surgery
and radiation therapy; however, statistical data point that 186,320
men will be diagnosed with cancer of the prostate and 28,660 men
will die due to this cancer in 2008 (http://seer.cancer.gov/statfacts/
html/prost.html). Prostate-specific antigen (PSA) is a serine protease secreted at high levels by prostate cancer cells making it a
potential target for immunotherapeutic approaches.
DNA-based vaccines have been shown to induce CTLs specific
for prostate antigens. A phase I clinical trial previously revealed
that vaccination with a PSA DNA vaccine in patients with prostate cancer is safe and can induce cellular and humoral immune
responses against PSA protein.72,73 The technique of EP has been
investigated as a more effective way for delivering PSA DNA
vaccines.74,75 In mice, the ID EP of a prostate cancer DNA vaccine encoding PSA resulted in 100- to 1,000-fold increased gene
expression and higher levels of PSA-specific T cells, compared to
589
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DNA delivery alone.75 Further investigations demonstrated that
ID DNA vaccination with small amounts of DNA followed by two
sets of electrical pulses of different length and voltage, effectively
induced PSA-specific T cells.74
Currently, there is one clinical trial examining the ability of EP
to enhance the effectiveness of vaccination against prostate cancer.
Interim data from the clinical study suggest that the treatment is
safe and well tolerated and that higher levels of antibody as well
as CD4+ and CD8+ T cells were detected in patients treated with
EP. Tolerability of the procedure was also documented in this trial.
Patients were given a choice between simple IM vaccination and
repeat EP—all patients chose repeat EP. The heightened immune
responses in patients treated using EP further validate the efficacy
of this DNA vaccine delivery method (http://www.medicalnewstoday.com/articles/102919.php).

Preclinical Applications Of Ep For Future
Clinical Use
There are several preclinical studies that have investigated EP
but have not yet made it to the clinical trial stage. The injection
of plasmid DNA in the retina with and without EP in vivo and
in vitro was carried out in rodents. Appropriate expression patterns and long-term expression of the constructs carrying retinal cell type–specific promoters was observed.76,77 The retina is
an interesting target system for the study of neural development
and treatment of disease and is being pursued for transition to
humans. Another promising area is that of inflammatory disease,
in particular rheumatoid arthritis, where EP of plasmids encoding
for human tumor necrosis factor alpha–soluble receptor I variants
(hTNFR-Is) were shown to exert protective effects, with decreased
joint destruction in the ankles.78
Other studies are investigating the use of EP for vaccination against influenza virus. An optimized H5N1 hemagglutinin
(HA)-based DNA vaccine administered by IM EP was shown to
elicit antibodies that neutralized a panel of virions from various
H5N1 viruses and protected the immunized mice from H5N1
virus challenges.79 In a separate study mice, ferrets and nonhuman primates were immunized by combining several consensus influenza antigens with in vivo EP inducing both protective
cellular and humoral immune responses. Furthermore, in a ferretchallenge model, vaccination with EP protected against morbidity and mortality.80 The continued development and transition
to clinical trial status of such research will be important for the
expansion and success of DNA vaccination with EP.

© The American Society of Gene Therapy

for EP-assisted delivery of plasmid DNA enabling the transition to
phase II and III studies and ultimately for use in clinical practice.
Interim data from some of the current clinical trials as discussed
suggest that the technique of EP for the administration of DNA
vaccines and immunotherapies is a powerful tool for combating
diseases. Not only does EP enhance humoral and cellular immune
responses, but it also decreases injection volume, minimizes the
number of applications, and prolongs the vaccine or therapeutic
effects. The route of administration will also likely play a large
role in the transition of EP to humans. Although most preclinical
studies to date have centered on IM applications, the ID route of
application will likely be more readily accepted by the majority
of the population. Together with the fact that skin administration
has been the status quo for vaccinations, the ease of accessibility and the reduced pain level compared to IM injections may
increase public acceptance. Evolution of the EP device itself from
a lab-like instrument to an esthetically pleasing, biosafe medical
tool that is easily operated and portable with low-cost disposables
will also be necessary for its future widespread use. Therefore, the
further development and application of EP will be of significant
importance in administration of vaccines to the public, in terms
of compliance and economical feasibility.
The most current developments in the field of EP are targeted
toward therapeutic applications. However, the one ongoing prophylactic vaccine study and many preclinical studies targeted to
prophylaxis suggest that using EP technology for prophylactic
applications may be feasible, depending on application, safety, and
tolerability data. Overall, the further understanding and development of EP will play an important role in advancing the use of
DNA vaccinations as well as the administration of DNA-based
immunotherapies or other therapeutic approaches.
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